Kano Therapeutics co-founders John Vroom and Floris Engelhardt
Exclusive: MIT spinout launches with focus on improving DNA payloads for gene insertion
We often imagine DNA as a stringlike molecule that’s easily scrunched up. But our six-foot-long genomes only fit inside our cells thanks to an intricate …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.